Two treatment regimens improve quality of life among patients with DLBCL
Click Here to Manage Email Alerts
NEW ORLEANS — Health-related quality of life in patients with diffuse large B-cell lymphoma improved in a comparison of two therapy regimens.
In both regimens — Pola-R-CHP (polatuzumab vedotin [Polivy, Genentech], rituximab, cyclophosphamide, doxorubicin and prednisone) and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) — patients reported similar improvements, according to a poster presented at ASH Annual Meeting and Exhibition.
"Both regimens led to significant improvements in health-related quality of life and rapid improvements, upon institution of treatment, in symptom scores, that were sustained through to end of treatment," Jonathan W. Friedberg, MD, MMSc, said during the poster presentation, which utilized data from the phase 3 POLARIX study.
"These improvements were seen in the majority of patients after cycle one and were maintained in most patients," Friedberg, director of the James P. Wilmot Cancer Institute and director of hematological malignancies clinical research, and the Samuel E. Durand chair in medicine at University of Rochester Medical Center, said.
A total of 879 patients with previously untreated DLBCL were randomly assigned to each study arm. Patient lymphoma symptoms were evaluated using the Functional Assessment of Cancer Therapy-Lymphoma Subscale. Additional symptoms, such as fatigue, constipation, diarrhea, nausea and vomiting, were evaluated with the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire. Researchers reported a high rate of questionnaire responses, with more than 80% of patients responding.
Clinically significant improvements were seen in 82.3% of patients receiving Pola-R-CHP and 81.3% of patients receiving R-CHOP at any given time throughout the duration of the study. Improvement scores began to plateau by the first assessment after treatment ceased.
Researchers reported similar functioning and fatigue scores at baseline in both arms and similar improvement during treatment.
Collapse
Friedberg J, et al. Poster 2949. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Click Here to Manage Email Alerts